Selected clinical characteristics pre- and peri-HSCT in patients undergoing transplantation for SCN
| Variable . | N (%) cases with available information . | . | N . | %* . |
|---|---|---|---|---|
| HSCT donor | 136 (100) | HLA-matched related donor | 61 | 45 |
| HLA-MUD | 61 | 45 | ||
| Mismatched donor | 14 | 10 | ||
| Stem cell source | 136 (100) | BM | 79 | 58 |
| CB | 24 | 18 | ||
| BP | 33 | 24 | ||
| Conditioning regimen† | 134 (98) | Myeloablative | 117 | 87 |
| RIC | 17 | 13 | ||
| GVHD prophylaxis | 114 (84) | CSA only/no CSA | 66 | 58 |
| CSA + methotrexate | 48 | 42 | ||
| In vivo T-cell depletion (ATG) | 136 (100) | Yes | 81 | 60 |
| No | 55 | 40 | ||
| Mutation | 65 (48) | ELANE | 39 | 60 |
| HAX1 | 5 | 8 | ||
| G6PC3 | 2 | 3 | ||
| No mutation | 19 | 29 | ||
| G-CSF given before HSCT | 98 (72) | Yes | 98 | 100 |
| No | 0 | 0 | ||
| G-CSF before HSC >5 mcg/kg | 70 (51) | Yes | 55 | 79 |
| No | 15 | 21 | ||
| Infections prior to HSCT | 86 (62) | None | 10 | 11 |
| Skin/subcutaneous/mouth | 23 | 27 | ||
| Lung and ear | 30 | 35 | ||
| Sepsis/meningitis/liver/gastrointestinal/bone abscesses | 23 | 27 | ||
| Hospitalization for infections prior to HSCT | 79 (58) | Yes | 66 | 84 |
| No | 13 | 16 | ||
| AL/MDS at HCST | 87 (64) | Yes | 14 | 16 |
| No | 73 | 84 | ||
| Median ANC 1 y before HSCT | 72 (53) | <0.5 × 109/L | 53 | 74 |
| 0.5-1.0 × 109/L | 11 | 15 | ||
| ≥1.0 × 109/L | 8 | 11 |
| Variable . | N (%) cases with available information . | . | N . | %* . |
|---|---|---|---|---|
| HSCT donor | 136 (100) | HLA-matched related donor | 61 | 45 |
| HLA-MUD | 61 | 45 | ||
| Mismatched donor | 14 | 10 | ||
| Stem cell source | 136 (100) | BM | 79 | 58 |
| CB | 24 | 18 | ||
| BP | 33 | 24 | ||
| Conditioning regimen† | 134 (98) | Myeloablative | 117 | 87 |
| RIC | 17 | 13 | ||
| GVHD prophylaxis | 114 (84) | CSA only/no CSA | 66 | 58 |
| CSA + methotrexate | 48 | 42 | ||
| In vivo T-cell depletion (ATG) | 136 (100) | Yes | 81 | 60 |
| No | 55 | 40 | ||
| Mutation | 65 (48) | ELANE | 39 | 60 |
| HAX1 | 5 | 8 | ||
| G6PC3 | 2 | 3 | ||
| No mutation | 19 | 29 | ||
| G-CSF given before HSCT | 98 (72) | Yes | 98 | 100 |
| No | 0 | 0 | ||
| G-CSF before HSC >5 mcg/kg | 70 (51) | Yes | 55 | 79 |
| No | 15 | 21 | ||
| Infections prior to HSCT | 86 (62) | None | 10 | 11 |
| Skin/subcutaneous/mouth | 23 | 27 | ||
| Lung and ear | 30 | 35 | ||
| Sepsis/meningitis/liver/gastrointestinal/bone abscesses | 23 | 27 | ||
| Hospitalization for infections prior to HSCT | 79 (58) | Yes | 66 | 84 |
| No | 13 | 16 | ||
| AL/MDS at HCST | 87 (64) | Yes | 14 | 16 |
| No | 73 | 84 | ||
| Median ANC 1 y before HSCT | 72 (53) | <0.5 × 109/L | 53 | 74 |
| 0.5-1.0 × 109/L | 11 | 15 | ||
| ≥1.0 × 109/L | 8 | 11 |